Persistent T-cell activation: A therapeutic option for alopecia areata - Singh, Vibhuti
52,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

Alopecia areata is a T-cell mediated autoimmune disease which mainly affects the anagen stage hair follicles, the most effective way of treating alopecia areata is the application of contact sensitizers which induces a mild chronic eczema (delayed type hypersensitivity). The curative effect of chronic eczema relies on the expansion of myeloid derived suppressor cells (MDSC) which can suppress the autoreactive T-cells and induces apoptosis of these via mitochondrial apoptotic pathway. Alternatively, a blockade of accessory molecules in T-cell activation could possibly be of therapeutic benefit.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Alopecia areata is a T-cell mediated autoimmune disease which mainly affects the anagen stage hair follicles, the most effective way of treating alopecia areata is the application of contact sensitizers which induces a mild chronic eczema (delayed type hypersensitivity). The curative effect of chronic eczema relies on the expansion of myeloid derived suppressor cells (MDSC) which can suppress the autoreactive T-cells and induces apoptosis of these via mitochondrial apoptotic pathway. Alternatively, a blockade of accessory molecules in T-cell activation could possibly be of therapeutic benefit. CD44 and CD49d being candidate accessory molecules since association of CD44 with CD49d plays an important role in homing of lymphocytes and blockade of these bystander pathways could be a therapeutic approach in alopecia areata.
Autorenporträt
Dr. Vibhuti Singh has obtained Ph.D. Degree in Natural Science in 2011. Previously she has worked with pharmaceutical company Ranbaxy Research Laboratories in drug discovery field. She has worked in the field of immunology, cell biology and molecular biology. She is the author of several research articles published in reputed scientific journals.